| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 14, 2016Studies show that treatment is less costly and has lower hospital re-admissions
Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia...
-
May 19, 2016Final, 5-year results from the EVOLVE Trial evaluating the Boston Scientific (NYSE: BSX) SYNERGY Stent support long-term safety and efficacy for the treatment of patients with de novo coronary artery disease.
The final 5 year results of the EVOLVE Trial reinforce earlier findings of sustained performance of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System, with no stent thrombosis (ST), a...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 17, 2016Outcomes from this post market study of more than 1,000 patients demonstrate the safety and efficacy of transcatheter aortic valve implantation (TAVI) with the LOTUS™ Valve in routine clinical practice.
Results from the RESPOND Study evaluating the Boston Scientific (NYSE: BSX) LOTUS™ Valve demonstrated excellent outcomes of key safety and efficacy endpoints through 30 days post implant...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...